european union flag

The aim of the project is to develop and globaly introduce OvaRenew, capsule for restoration of the impaired egg quality and quantity in woman with ovarian insufficiency, as a first-line therapy. Our solution is based on new disruptive findings of stem cells in ovaries that are able to transform into oocytes under defined conditions. We tend to prove, that those conditions can be initiated through the substances, administered orally. Thus OvaRenew will enable women with impaired egg quality to produce their own child while drastically decreasing cost and invasiveness of the procedures on one and country health and other expenditures on the other hand.


• Premature ovarian insufficiency (POI) patients account for 1 % of women between 18-44 years old. They are under strict medical supervision, with other serious medical complications. Only 5-10 % conceive without medical assistence.

• Patients with diminished ovarian reserve (DOR) are usually consequence of ovarian surgery, cancer treatment and bad lifestyle factors like smoking and obesity. Their status is usually defined while trying to conceive with medically assisted reproduction techniques, therefore under fertility specialist's supervision, too, but with up to 20 % chances of conceival.

• Otherwise healthy women that are trying to conceive after 35 years old accounts for 7-8 % of women between 18-44 years old.

Effect on egg quality and quantity will be enabled by candidate substance, taken with capsule. The candidate substance's presence in the follicular fluid is known to be critically important for the egg quality and correlated with the intake. Follicular fluid is an important microenvironment for the development of oocytes. Stem cells develop according to the environment they are in. Increased values of candidate substance in human follicular fluid as a result of increased intake corelate well with increased values of some important growth factors and reproductive hormones and are shown to increase maturity of oocytes in women under MAR procedures. Those are proven to trigger transformation of stem cells into oocytes even in unsufficient ovary. With clinical study, we intend to prove the efficacy of candidate substance on egg quality in egg impaired women, under defined, controlled conditions.